Matrix Capital Management

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Rivos is a startup focused on developing high-performance RISC-V systems aimed at providing integrated solutions for enterprises. The company manufactures computing chips designed to deliver efficient and powerful server systems tailored for large language models and data analytics. Rivos offers a comprehensive RISC-V-based server solution that includes optimized processors, a data parallel accelerator, and an open software stack. This platform enables developers to effectively deploy existing workloads, enhancing performance, security, and overall cost efficiency.

Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their complexity and difficulty in management. The company has developed a proprietary peptide-based platform designed to diagnose and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic, therapeutic, and anti-biofilm applications, particularly aimed at the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By focusing on early detection and effective treatment strategies, AltPep aims to enhance healthcare outcomes related to amyloid diseases, ultimately improving human health.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Monod Bio is a life sciences company headquartered in Seattle, Washington, specializing in the development of innovative biosensors for the detection of proteins, toxins, antibodies, and other analytes. Founded in 2021, the company leverages advances in computational protein engineering to create modular bio-sensing nanoswitches. These biosensors integrate binding, transduction, and amplification processes in a single step, allowing for rapid, sensitive, and cost-effective analytical assays. Monod Bio's technology aims to enhance the capabilities of the healthcare industry by providing advanced tools for biotechnology and medical applications.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Talos Trading is an institutional technology infrastructure provider based in New York, co-founded in 2018 by Anton Katz and Ethan Feldman. The company specializes in offering a comprehensive crypto trading platform that supports the entire trading lifecycle, including price discovery, clearing, and settlement. Talos Trading provides solutions across spot, futures, and foreign exchange markets, leveraging institutional-grade technology to enable clients to stream real-time and request-for-quote prices. Additionally, the platform includes portfolio accounting tools and facilitates efficient settlement processes, connecting various participants within the crypto ecosystem.

Koneksa Health Inc. is a healthcare data analytics company that specializes in designing and developing software solutions for pharmaceutical and biotech firms. The company’s flagship product, Koneksa Compare, facilitates the collection, monitoring, and analysis of patient-generated data to support clinical studies and regulatory claims. By integrating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires, Koneksa enhances the accuracy and breadth of data that researchers can analyze, thereby minimizing subjective biases in clinical endpoints. Additionally, the platform provides a dashboard that offers electronic clinical outcome assessments and reminders for study participants. Established in 2013 and headquartered in New York, Koneksa also maintains a presence in London, United Kingdom, and is recognized for its contributions to improving the efficiency of drug development through innovative data analysis.

Blockdaemon Inc. is a blockchain node management platform that enables businesses, enterprises, and developers to efficiently deploy and manage blockchain applications. Founded in 2013 and headquartered in Los Angeles, California, with additional offices in New York and Ireland, the company provides tools that allow users to manage nodes across more than 30 blockchain protocols, including Bitcoin, Ethereum, and Polkadot. Blockdaemon's solution is designed to be fully portable, enabling users to easily switch between networks and chains without the need for extensive configuration. The company also supports the blockchain developer ecosystem by offering expert dev-ops advice, facilitating smoother integration and deployment in the rapidly evolving blockchain landscape.

Solve Therapeutics is a biopharmaceutical company based in Belmont, California, founded in 2021. The company specializes in the development of first-in-class antibody-drug conjugates and bispecific therapeutics. With a team of experienced professionals, Solve Therapeutics aims to create innovative biopharmaceutical medicines that address significant unmet medical needs, ultimately enhancing patient outcomes and quality of life.

Maze Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, established in 2017. The company specializes in developing genetic modifier therapeutics aimed at addressing unmet medical needs. Utilizing its innovative Compass platform, Maze Therapeutics focuses on identifying rare genetic variants that offer protective effects against diseases. By analyzing large-scale human genetic data and employing functional genomics, the company maps these variants to the biological pathways that contribute to specific conditions in patient populations. This approach enables a deeper understanding of target biology and facilitates the development of novel therapies, positioning Maze Therapeutics as a key player in translating genetic insights into effective medicines.

Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

Pramana, Inc. is a health technology company focused on transforming digital pathology for medical centers and pathology labs. It offers a comprehensive Digital Pathology as a Service (DPaaS) solution, which includes advanced whole slide imaging systems and a scalable software platform designed to enhance clinical workflows. By integrating the hardware capabilities acquired from Spectral Insights and the software expertise of nference, Pramana provides pathologists with access to AI-enabled decision support tools. This innovative approach allows medical professionals to obtain high-quality imaging while minimizing operational challenges, ultimately aiming to improve patient care on a global scale.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Bardavon Health Innovations, LLC specializes in healthcare technology and services specifically designed for managing workers’ compensation cases. Established in 2013 and based in Overland Park, Kansas, the company offers a comprehensive approach to workers’ compensation, facilitating the management of the entire employee lifecycle, from hire to retirement. Its technology connects employers with essential tools and information, enabling informed decisions regarding employees in injury risk positions. Bardavon’s solutions enhance communication among therapy providers, referral sources, and other stakeholders, while simplifying reporting, data tracking, and job analysis. The company’s product offerings include bNOTES, bNOTES Connect, Telerehabilitation, Clinical Consulting, Job Analysis, Post-Offer Employment Testing, and XRTS Effort Assessment. By providing real-time updates on patient status and justifying the need for therapy treatment, Bardavon aims to empower quality healthcare decisions through improved transparency and collaboration.

Blockdaemon Inc. is a blockchain node management platform that enables businesses, enterprises, and developers to efficiently deploy and manage blockchain applications. Founded in 2013 and headquartered in Los Angeles, California, with additional offices in New York and Ireland, the company provides tools that allow users to manage nodes across more than 30 blockchain protocols, including Bitcoin, Ethereum, and Polkadot. Blockdaemon's solution is designed to be fully portable, enabling users to easily switch between networks and chains without the need for extensive configuration. The company also supports the blockchain developer ecosystem by offering expert dev-ops advice, facilitating smoother integration and deployment in the rapidly evolving blockchain landscape.

GentiBio, Inc. is a biotherapeutics company that specializes in developing engineered regulatory T cells, known as EngTregs, aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, Washington, GentiBio employs a proprietary platform that combines autologous and allogeneic technologies. This platform enhances the ability to restore immune tolerance and addresses significant limitations found in existing regulatory T-cell therapeutics. By focusing on the underlying mechanisms of immune system disorders, GentiBio aims to provide innovative therapeutic solutions that tackle the root causes of diseases caused by dysregulated immune responses. The company is co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of advanced immunotherapy development.

Emboline, Inc. is a medical device company focused on developing innovative cardiovascular embolic protection devices for a variety of transcatheter and surgical cardiac procedures. Founded in 2011 and based in Santa Cruz, California, the company has created technologies such as Emboline Complete Accessible Protection, which provides embolic protection for the arterial bed, and the Emboliner, an embolic protection catheter designed to safeguard cerebral arteries. These products are particularly beneficial during percutaneous heart valve repair and replacement procedures, as well as in interventional cardiology and electrophysiology markets. Emboline's devices are engineered to conform to diverse patient anatomies and include features that allow for the capture and removal of emboli, thereby enhancing the safety of critical medical procedures.

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies aimed at targeting and destroying cancer cells through viral nanoparticle conjugates. The company's lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary cancer of the eye. Aura Biosciences aims to address the challenges of treating small ocular melanomas early in the disease progression to prevent metastasis, particularly to the liver, which is often fatal. In addition to ocular oncology, the company is exploring applications of its platform in other indications, including bladder cancer. Founded in 2007, Aura Biosciences is committed to advancing precision immunotherapies designed to preserve organ function while effectively managing a range of solid tumors.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their complexity and difficulty in management. The company has developed a proprietary peptide-based platform designed to diagnose and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic, therapeutic, and anti-biofilm applications, particularly aimed at the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By focusing on early detection and effective treatment strategies, AltPep aims to enhance healthcare outcomes related to amyloid diseases, ultimately improving human health.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Palleon Pharmaceuticals Inc. is a biotechnology company dedicated to developing innovative therapeutics that target glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in glycoimmune checkpoint inhibitors, leveraging advanced insights from glycoscience and human immunology. Palleon's biotechnology platform aims to provide a novel approach to cancer treatment by targeting various immune cell types, thus offering physicians an expanded array of combination therapies to enhance treatment efficacy and address resistance to existing immuno-oncology agents. In addition to cancer, the company also focuses on therapeutics for inflammatory diseases, including autoimmunity and fibrosis.

Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. Utilizing its proprietary platform, the company identifies genomic sequences that regulate gene expression, facilitating advancements in viral gene therapy. Encoded Therapeutics has a diverse therapy pipeline targeting various genetic and acquired disorders across multiple disease pathways, including neurocircuitry, metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, the company is dedicated to improving patient outcomes through innovative gene therapy solutions.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. Utilizing its proprietary platform, the company identifies genomic sequences that regulate gene expression, facilitating advancements in viral gene therapy. Encoded Therapeutics has a diverse therapy pipeline targeting various genetic and acquired disorders across multiple disease pathways, including neurocircuitry, metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, the company is dedicated to improving patient outcomes through innovative gene therapy solutions.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Qrativ Inc., established in 2017 and headquartered in Cambridge, Massachusetts, specializes in developing an AI-driven healthcare platform focused on identifying potential treatments for rare diseases. The company's core product is a drug purposing platform designed to revolutionize how therapies for unmet medical needs are discovered and developed. This platform, Darwin.ai, employs machine learning and artificial intelligence to uncover new uses for existing molecules, aiming to provide treatments for conditions where market-available drugs are lacking. Qrativ serves biotechnology and pharmaceutical companies with this innovative solution.

EpiBiome, Inc. is a precision microbiome engineering company based in South San Francisco, California, founded in 2013. The company is dedicated to developing therapies that address infectious diseases in humans and agriculture without relying on small-molecule antibiotics. EpiBiome focuses on phage therapy, which targets specific strains within the microbiome, effectively treating antibiotic-resistant infections. Its applications include treatment for mastitis in dairy cows and addressing infections caused by Escherichia coli in humans. By utilizing advanced sequencing and bioinformatic processes, EpiBiome aims to identify pathogenic bacteria and microbiome changes that contribute to disease, offering innovative alternatives to combat the rising threat of antibiotic resistance. As of July 2018, it operates as a subsidiary of Locus Biosciences, Inc.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Adaptive Biotechnologies Corporation is a commercial-stage company focused on advancing immune-driven medicine by leveraging the biology of the adaptive immune system to enhance disease diagnosis and treatment. Established in 2009 and headquartered in Seattle, Washington, the company offers a range of products and services, including its FDA-authorized clonoSEQ diagnostic test, which is designed for the detection and monitoring of minimal residual disease in patients with specific blood cancers, such as multiple myeloma and chronic lymphocytic leukemia. In addition to clonoSEQ, Adaptive Biotechnologies provides immunoSEQ research services and kits to support scientific research and the discovery of new diagnostic signals. The company also has a pipeline of clinical products aimed at diagnosing and managing various diseases, including cancers, autoimmune disorders, and infectious diseases. It maintains strategic collaborations with notable partners such as Genentech and Microsoft to develop innovative therapies and diagnostic tests.

Xero Limited is a New Zealand-based technology company that specializes in cloud-based accounting software designed for small and midsize enterprises, as well as accounting practices. Founded in 2006 and headquartered in Wellington, Xero offers a comprehensive suite of tools, including its core accounting software, a mobile app, and various solutions for accountants and bookkeepers, such as Xero HQ and Xero Practice Manager. The platform enables users to efficiently manage cash flow, invoicing, payments, and reporting through a subscription model with three tiers: starter, standard, and premium. Xero has established a strong market presence in New Zealand and Australia, successfully competing against traditional accounting software providers, and has expanded its services to other English-speaking countries, particularly the United Kingdom.

Xero Limited is a New Zealand-based technology company that specializes in cloud-based accounting software designed for small and midsize enterprises, as well as accounting practices. Founded in 2006 and headquartered in Wellington, Xero offers a comprehensive suite of tools, including its core accounting software, a mobile app, and various solutions for accountants and bookkeepers, such as Xero HQ and Xero Practice Manager. The platform enables users to efficiently manage cash flow, invoicing, payments, and reporting through a subscription model with three tiers: starter, standard, and premium. Xero has established a strong market presence in New Zealand and Australia, successfully competing against traditional accounting software providers, and has expanded its services to other English-speaking countries, particularly the United Kingdom.

Xero Limited is a New Zealand-based technology company that specializes in cloud-based accounting software designed for small and midsize enterprises, as well as accounting practices. Founded in 2006 and headquartered in Wellington, Xero offers a comprehensive suite of tools, including its core accounting software, a mobile app, and various solutions for accountants and bookkeepers, such as Xero HQ and Xero Practice Manager. The platform enables users to efficiently manage cash flow, invoicing, payments, and reporting through a subscription model with three tiers: starter, standard, and premium. Xero has established a strong market presence in New Zealand and Australia, successfully competing against traditional accounting software providers, and has expanded its services to other English-speaking countries, particularly the United Kingdom.

Tenor Networks, Inc. is a company that specializes in the development and manufacturing of optical switching systems. The firm offers products such as the TN250G, a Core MPLS Switch, and TEMPo, an element management platform designed for managing optical networks. In addition to its hardware, Tenor Networks provides service intelligence solutions that enhance the performance and efficiency of communication networks. The company's focus on advanced optical technologies positions it as a key player in the telecommunications equipment market.